KCNQ2
Potassium voltage-gated channel subfamily KQT member 2
Also known as: BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, KCNQ2_HUMAN, Kv7.2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O43526
- Gene
- KCNQ2
- Ensembl
- ENSG00000075043
- Chromosome
- 20
- Canonical length
- 872 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels
- Subcellular location
- Endoplasmic reticulum
OverviewNCBI Gene
The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
872 residues, UniProt reviewed canonical sequence.
>O43526|KCNQ2
1 MVQKSRNGGV YPGPSGEKKL KVGFVGLDPG APDSTRDGAL LIAGSEAPKR GSILSKPRAG
61 GAGAGKPPKR NAFYRKLQNF LYNVLERPRG WAFIYHAYVF LLVFSCLVLS VFSTIKEYEK
121 SSEGALYILE IVTIVVFGVE YFVRIWAAGC CCRYRGWRGR LKFARKPFCV IDIMVLIASI
181 AVLAAGSQGN VFATSALRSL RFLQILRMIR MDRRGGTWKL LGSVVYAHSK ELVTAWYIGF
241 LCLILASFLV YLAEKGENDH FDTYADALWW GLITLTTIGY GDKYPQTWNG RLLAATFTLI
301 GVSFFALPAG ILGSGFALKV QEQHRQKHFE KRRNPAAGLI QSAWRFYATN LSRTDLHSTW
361 QYYERTVTVP MYSSQTQTYG ASRLIPPLNQ LELLRNLKSK SGLAFRKDPP PEPSPSKGSP
421 CRGPLCGCCP GRSSQKVSLK DRVFSSPRGV AAKGKGSPQA QTVRRSPSAD QSLEDSPSKV
481 PKSWSFGDRS RARQAFRIKG AASRQNSEEA SLPGEDIVDD KSCPCEFVTE DLTPGLKVSI
541 RAVCVMRFLV SKRKFKESLR PYDVMDVIEQ YSAGHLDMLS RIKSLQSRVD QIVGRGPAIT
601 DKDRTKGPAE AELPEDPSMM GRLGKVEKQV LSMEKKLDFL VNIYMQRMGI PPTETEAYFG
661 AKEPEPAPPY HSPEDSREHV DRHGCIVKIV RSSSSTGQKN FSAPPAAPPV QCPPSTSWQP
721 QSHPRQGHGT SPVGDHGSLV RIPPPPAHER SLSAYGGGNR ASMEFLRQED TPGCRPPEGN
781 LRDSDTSISI PSVDHEELER SFSGFSISQS KENLDALNSC YAAVAPCAKV RPYIAEGESD
841 TDSDLCTPCG PPPRSATGEG PFGDVGWAGP RKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KCNQ2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.56
- Highest tissue expression
- 136 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 136 nTPM
- hippocampal formation: 94 nTPM
- cerebral cortex: 94 nTPM
- amygdala: 92 nTPM
- basal ganglia: 72 nTPM
- hypothalamus: 42 nTPM
Single-cell type
- oligodendrocyte progenitor cells: 100 nCPM
- brain excitatory neurons: 92 nCPM
- brain inhibitory neurons: 79 nCPM
- adrenal medulla cells: 75 nCPM
- other brain neurons: 50 nCPM
- undifferentiated spermatogonia: 33 nCPM
Immune cell
- memory CD4 T-cell: 0.4 nTPM
- T-reg: 0.2 nTPM
- naive CD4 T-cell: 0.1 nTPM
- naive CD8 T-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
Brain region
- cerebral cortex: 353 nTPM
- hippocampal formation: 316 nTPM
- amygdala: 288 nTPM
- cerebellum: 234 nTPM
- basal ganglia: 231 nTPM
- white matter: 196 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about KCNQ2.
Disease | AllUniProt
Conditions KCNQ2 is implicated in, by any mechanism.
- Seizures, benign familial neonatal 1 (BFNS1) MIM:121200
- Developmental and epileptic encephalopathy 7 (DEE7) MIM:613720
Disease | GeneticClinVar
760 pathogenic / likely-pathogenic of 2,395 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Early-infantile DEE
- Developmental and epileptic encephalopathy, 7
- Seizures, benign familial neonatal, 1
- Complex neurodevelopmental disorder
- Inborn genetic diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.16
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.04
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- action potential
- chemical synaptic transmission
- nervous system development
- potassium ion transmembrane transport
Molecular functions
- ankyrin binding
- calmodulin binding
- voltage-gated monoatomic cation channel activity
- voltage-gated potassium channel activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Potassium channel, voltage dependent, KCNQ
- Ion transport domain
- Potassium channel, voltage dependent, KCNQ, C-terminal
- Ankyrin-G binding site
- Ion transport protein
- KCNQ voltage-gated potassium channel
- Ankyrin-G binding motif of KCNQ2-3
- Potassium channel, voltage dependent, KCNQ2
- Unstructured region on Potassium channel subunit alpha KvLQT2
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of KCNQ2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KCNQ2 as an antibody target. Whether an autoantibody or antibody against KCNQ2 could matter depends on whether native KCNQ2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KCNQ2 is annotated at the cell surface, where native KCNQ2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label KCNQ2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...